ANALISIS EFEKTIVITAS DAN BIAYA PENGGUNAAN SITIKOLIN DAN PIRASETAM PADA PASIEN STROKE ISKEMIK DI BANGSAL RAWAT INAP RSUD UNDATA PALU
| Main Authors: | , Nur Santi, , Prof. Dr. Zullies Ikawati, Ph.D., Apt. |
|---|---|
| Format: | Thesis NonPeerReviewed |
| Terbitan: |
[Yogyakarta] : Universitas Gadjah Mada
, 2013
|
| Subjects: | |
| Online Access: |
https://repository.ugm.ac.id/123254/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=63365 |
Daftar Isi:
- One of therapy in the treatment of ischemic stroke patients is neuroprotektan ie citicoline and piracetam with a very large amount of usage. Cost of drugs - the drugs most in the treatment of stroke, while the effectiveness of the two drugs against neurological improvement ischemic stroke patients is still controversial. This study aims to determine the comparative effectiveness between citicoline and piracetam in ischemic stroke patients and analyze the cost of care. This study uses a non-experimental cohort design. Data captured prospectively studied ischemic stroke patients in inpatient wards Undata Palu Hospital during November 2012-February 2013. Citikolin therapeutic effectiveness and piracetam to repair neurological function assessed by GCS (Glasgow Coma Scale) and then analyzed by calculating the cost of care of medical costs (direct medical costs). The results showed no difference in the effectiveness of ischemic stroke patients who received therapy citicoline compared with pirasetam to repair neurological function with a value of 0.295 significance (p> 0,05). The average total cost of the drug and the group citicoline piracetam sequence is Rp 413.584±180.637 and Rp 616.548±182.348, the average cost of non-drug group and pirasetam sitikolin sequence is Rp 2,200,208 and Rp 2,580,287, the average total cost of care in sitikolin groups and pirasetam sequence is Rp 2,613,792 and Rp 3,196,835.